{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["10(10)"],"submitter":["Moghnieh R"],"pubmed_abstract":["In this study involving a cohort of employees of the National Airline company in Lebanon, we assessed humoral immunity levels and the effectiveness of two COVID-19 vaccines, Gam-COVID-Vac versus BNT162b2, after two doses and after a homologous and heterologous BNT162b2 booster, in addition to the impact of hybrid immunity. Vaccine effectiveness (VE) was retrospectively determined against laboratory-confirmed SARS-CoV-2 infection during the periods of Delta and Omicron variants' predominance, separately, and was calculated based on a case-control study design. The humoral immune response, measured by a SARS-CoV-2 anti-spike receptor-binding domain (RBD) IgG titer, was prospectively assessed after the aforementioned vaccination schemes at different time points. This study showed higher effec"],"journal":["Vaccines"],"pagination":["1596"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9607825"],"repository":["biostudies-literature"],"pubmed_title":["Immunogenicity and Effectiveness of Primary and Booster Vaccine Combination Strategies during Periods of SARS-CoV-2 Delta and Omicron Variants."],"pmcid":["PMC9607825"],"pubmed_authors":["Moghnieh R","Bizri AR","El Hajj C","Sayegh MH","Jbeily N","Abdallah D"],"additional_accession":[]},"is_claimable":false,"name":"Immunogenicity and Effectiveness of Primary and Booster Vaccine Combination Strategies during Periods of SARS-CoV-2 Delta and Omicron Variants.","description":"In this study involving a cohort of employees of the National Airline company in Lebanon, we assessed humoral immunity levels and the effectiveness of two COVID-19 vaccines, Gam-COVID-Vac versus BNT162b2, after two doses and after a homologous and heterologous BNT162b2 booster, in addition to the impact of hybrid immunity. Vaccine effectiveness (VE) was retrospectively determined against laboratory-confirmed SARS-CoV-2 infection during the periods of Delta and Omicron variants' predominance, separately, and was calculated based on a case-control study design. The humoral immune response, measured by a SARS-CoV-2 anti-spike receptor-binding domain (RBD) IgG titer, was prospectively assessed after the aforementioned vaccination schemes at different time points. This study showed higher effec","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Sep","modification":"2025-04-03T21:29:58.055Z","creation":"2025-04-03T21:29:58.055Z"},"accession":"S-EPMC9607825","cross_references":{"pubmed":["36298460"],"doi":["10.3390/vaccines10101596"]}}